Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Kamada Ltd. (KMDA : NSDQ)
 
 • Company Description   
Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel.

Number of Employees: 420

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.70 Daily Weekly Monthly
20 Day Moving Average: 73,960 shares
Shares Outstanding: 57.51 (millions)
Market Capitalization: $442.79 (millions)
Beta: 0.96
52 Week High: $9.16
52 Week Low: $5.08
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 10.16% 6.85%
12 Week 22.42% 6.12%
Year To Date 26.44% 19.45%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2 HOLTZMAN ST. SCIENCE PARK
-
REHOVOT,L3 7670402
ISR
ph: 972-8940-6472
fax: 972-8940-6473
ir@kamada.com http://www.kamada.com
 
 • General Corporate Information   
Officers
Amir London - Chief Executive Officer
Lilach Asher-Topilsky - Chair of the Board of Directors
Eran Nir - Chief Operating Officer
Chaime Orlev - Chief Financial Officer
Uri Botzer - Director

Peer Information
Kamada Ltd. (CORR.)
Kamada Ltd. (RSPI)
Kamada Ltd. (CGXP)
Kamada Ltd. (BGEN)
Kamada Ltd. (GTBP)
Kamada Ltd. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: M6240T109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 57.51
Most Recent Split Date: (:1)
Beta: 0.96
Market Capitalization: $442.79 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.09 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.33 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 25.00% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 23.33
Trailing 12 Months: 26.55
PEG Ratio: 0.93
Price Ratios
Price/Book: 1.76
Price/Cash Flow: 15.66
Price / Sales: 2.65
EPS Growth
vs. Year Ago Period: 75.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: 16.65%
vs. Previous Quarter: 12.85%
ROE
06/30/25 - -
03/31/25 - 6.31
12/31/24 - 5.71
ROA
06/30/25 - -
03/31/25 - 4.43
12/31/24 - 4.08
Current Ratio
06/30/25 - -
03/31/25 - 3.30
12/31/24 - 3.73
Quick Ratio
06/30/25 - -
03/31/25 - 1.93
12/31/24 - 2.14
Operating Margin
06/30/25 - -
03/31/25 - 9.60
12/31/24 - 8.99
Net Margin
06/30/25 - -
03/31/25 - 9.60
12/31/24 - 8.99
Pre-Tax Margin
06/30/25 - -
03/31/25 - 10.47
12/31/24 - 8.28
Book Value
06/30/25 - -
03/31/25 - 4.38
12/31/24 - 4.51
Inventory Turnover
06/30/25 - -
03/31/25 - 1.21
12/31/24 - 1.16
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©